While an open-label, multicenter phase I trial of the LSD1 inhibitor, GSK2879552, was terminated after recruiting 29 patients due to toxicity and lack of response [112], clinical trials investigating combination therapies with LSD1 inhibitors are ongoing (NCT03850067, NCT05191797, NCT05420636), and selection for neuroendocrine-high SCLC patients may improve response (Table 1). The gene discussed is KDM1A; the disease is small cell lung carcinoma.